Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs.

Autor: De Chiara L; Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.; CINBIO, Universidade de Vigo, 36210 Vigo, Spain.; Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Vigo, Spain., Barcia-Castro L; Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain., Gallardo-Gómez M; Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain., Páez de la Cadena M; Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain., Martínez-Zorzano VS; Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain., Rodríguez-Berrocal FJ; Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain., Bujanda L; Department of Gastroenterology, Biodonostia Health Research Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain., Etxart A; Department of Surgery, Hospital Universitario Donostia, 20014 San Sebastián, Spain., Castells A; Gastroenterology Department, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, 08036 Barcelona, Spain., Balaguer F; Gastroenterology Department, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, 08036 Barcelona, Spain., Jover R; Department of Gastroenterology, Hospital General Universitario de Alicante, 03010 Alicante, Spain., Cubiella J; Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, CIBERehd, 32005 Ourense, Spain., Cordero OJ; Department of Biochemistry and Molecular Biology, CIBUS Building, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Sep 20; Vol. 14 (19). Date of Electronic Publication: 2022 Sep 20.
DOI: 10.3390/cancers14194563
Abstrakt: Fecal hemoglobin immunodetection (FIT) in combination with endoscopy has been implemented to reduce mortality from colorectal cancer (CRC), although there are issues that can be improved in relation to participation rates. We studied whether the blood biomarker soluble-CD26 (sCD26), related at least in part to the immune system and inflammation, and/or its dipeptidyl peptidase enzyme activity (DPP4), could help reduce false positives. In a cohort of 1703 individuals who underwent colonoscopy and had a serum sample, sCD26 and DPP4 activity showed statistically significant differences regarding sex and age. According to the colonoscopy findings, sCD26 and DPP4 activity progressively decreased in advanced adenomas and CRC, with statistically significant differences, even between both groups; 918 of them had a FIT result ( n = 596 positive cases) with approximately 70% of these ( n = 412) false positives. With cut-offs of 440 ng/mL for sCD26, 42 mU/mL for DPP4, and 11 ng/mU for their ratio, the combined information of the three biomarkers (at least positive for one biomarker) identified almost all advanced adenomas and CRC cases in the FIT cohort with approximately half of the false positives compared to FIT. A sequential testing strategy with FIT and our blood biomarker test is proposed.
Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Databáze: MEDLINE
Externí odkaz: